---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105015"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:03:34.272574+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arcellx reports 97% ORR from anito-cel Phase 2; FDA clears ACLX-004 IND; Q2 net loss $52.8M

## Summary
- Phase 2 iMMagine-1: 97% ORR, 68% CR/sCR at 12.6 months; no delayed neurotoxicity events observed.
- FDA cleared IND for ACLX-004 (CD33/CD123) ARC-SparX platform for AML.
- Q2 2025 net loss $52.8M vs $27.2M in Q2 2024; rev $7.6M (down from $27.4M).
- Cash $537.6M expected to fund operations into 2028.
- Plan to launch anito-cel at >160 US treatment centers within first year.

## SEC filing metadata
- accession: 0000950170-25-105015
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000095017025105015/0000950170-25-105015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000095017025105015/aclx-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105015
- JSON: https://secwatch.observer/filing/0000950170-25-105015.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.